DARZALEX/DARZALEX FASPRO is ~15% of total revenues and grew 23.0% in 2025; Genmab-licensed patents expire in US in 2029 with 12-20% royalty obligation.
Relevance 95·Dependency 75·Confidence 97
Source evidence
“Royalty rate ranges from 12% to 20% of total DARZALEX net sales. For the fiscal 2025 and 2024, royalty amounts to Genmab were approximately $2.4 billion and $2.0 billion, respectively.”
STELARA biosimilars
Competitive Exposure
Biosimilar competition drove STELARA sales down 41.3% to $6.1B and cut 6.2% from worldwide sales growth; further launches expected.
Relevance 90·Dependency 60·Confidence 97
Source evidence
“the negative impact of the STELARA sales decline, due to biosimilar competition, was approximately 6.2%, 7.6% and 4.4% on worldwide, U.S. and international operational sales”
Inflation Reduction Act of 2022
Revenue Exposure
IRA government-established Medicare pricing beginning 2026 and Part D redesign could reduce U.S. Innovative Medicine sales.
Relevance 85·Dependency 70·Confidence 95
Source evidence
“change to Medicare Part D could have a negative impact on U.S. Innovative Medicine sales.”
Three wholesalers
Customer Exposure
Three wholesalers distribute products for both segments and represent ~48% of total gross revenues, creating channel concentration risk.
Relevance 85·Dependency 60·Confidence 95
Source evidence
“the Company utilized three wholesalers distributing products for both segments that represented approximately 21.8%, 15.5% and 11.1% of the total gross revenues”
Talc body powders (JOHNSON’S Baby Powder)
Legal Exposure
Numerous talc lawsuits could require significant payments potentially in excess of accruals.
Relevance 85·Dependency 60·Confidence 96
Source evidence
“the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder”
Oncology is a named therapeutic area of the Innovative Medicine segment driving prescription product sales.
Relevance 85·Dependency 40·Confidence 90
Source evidence
“The Innovative Medicine segment is focused on the following therapeutic areas: Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolic.”
Third-party manufacturers and suppliers
Supplier Dependency
Reliance on third-party manufacturers for certain raw materials, components and products creates disruption and cost risk.
Relevance 80·Dependency 65·Confidence 93
Source evidence
“Any failure by or loss of a third-party manufacturer or supplier could result in delays and increased costs, which may adversely affect our business.”
Hospitals and healthcare professionals
Revenue Exposure
Both segments distribute through hospitals, wholesalers and healthcare professionals, making these channels key to revenue.
Relevance 80·Dependency 50·Confidence 90
Source evidence
“distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use”
Intra-Cellular Therapies, Inc.
Revenue Exposure
$14.5B acquisition closed April 2, 2025 drove ~$11.3B increase in total borrowings and higher net debt.
Relevance 75·Dependency 60·Confidence 95
Source evidence
“The increase in the borrowings was primarily due to the issuance of new debt in the fiscal first quarter of 2025.”
Acquired in-process R&D pipeline
Technology Dependency
Indefinite-lived purchased IPR&D of $15,619M and ongoing IPR&D acquisitions/milestones underpin the future Innovative Medicine pipeline.
Relevance 75·Dependency 55·Confidence 90
Source evidence
“Purchased in-process research and development15,61912,281”
Medicare Part D redesign
Cost Driver
Medicare Part D redesign repeatedly cited as an offset to growth across ERLEADA, IMBRUVICA, STELARA, INVEGA, OPSUMIT and UPTRAVI.
Relevance 75·Dependency 50·Confidence 90
Source evidence
“Growth of ERLEADA (apalutamide) was primarily due to continued share gains and market growth partially offset by the impact of Medicare Part D redesign.”
340B Federal Drug Discount Program
Revenue Exposure
Expanded interpretations and program abuse of 340B discounts may hurt financial performance.
Relevance 70·Dependency 55·Confidence 88
Source evidence
“increased third-party utilization of the 340B Federal Drug Discount Program from expanded interpretations of the statute and program abuse may have a negative impact on the Company's financial performance”
Genmab A/S
Technology Dependency
Genmab owns two DARZALEX patent families exclusively licensed to Janssen Biotech; royalties of ~$2.4B in 2025 at 12-20% of net sales.
Relevance 70·Dependency 55·Confidence 95
Source evidence
“Genmab A/S owns two patent families related to DARZALEX, and Janssen Biotech, Inc. ... has an exclusive license to those patent families.”
Cardiovascular (MedTech)
Revenue Exposure
Cardiovascular is a disclosed MedTech product field contributing to MedTech revenue.
Relevance 70·Dependency 30·Confidence 90
Source evidence
“The MedTech segment includes a broad portfolio of products used in the Surgery, Orthopaedic, Cardiovascular and Vision fields.”
Surgery (MedTech)
Revenue Exposure
Surgery is a disclosed MedTech product field used by physicians, nurses, hospitals and clinics.
Relevance 70·Dependency 30·Confidence 90
Source evidence
“used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics”
Company hedges FX via forwards and swaps; sensitivities quantified at ±$0.2B/-$0.3B for 10% USD move.
Relevance 65·Dependency 55·Confidence 90
Source evidence
“Conversely, a 10% depreciation of the U.S. Dollar from the December 28, 2025 market rates would decrease the unrealized value of the Company’s forward contracts by approximately $0.3 billion.”
Tax provision more than doubled to $5,777M in FY2025 from $2,621M, materially affecting net earnings.
Relevance 60·Dependency 40·Confidence 85
Source evidence
“Provision for taxes on income (Note 8)5,7772,6211,736”
SPRAVATO grew 57.4% to $1,696M on increased physician and patient demand, a key Neuroscience growth driver.
Relevance 60·Dependency 35·Confidence 90
Source evidence
“Growth of SPRAVATO (esketamine) was driven by continued increased physician and patient demand.”
SIMPONI biosimilars
Legal Exposure
At least two SIMPONI biosimilars pursuing US approval, which would likely significantly reduce future sales.
Relevance 55·Dependency 40·Confidence 90
Source evidence
“At least two biosimilars are pursuing regulatory approval for a SIMPONI biosimilar in the United States, which would likely result in a significant reduction in future sales.”